title: An update on pharmacologic management of chronic obstructive pulmonary disease.
abstract: OBJECTIVE
  Chronic obstructive pulmonary disease (COPD) is a widespread disease process with important clinical and economic implications. This review will summarize new pharmacotherapy for the treatment of COPD.
  
  
  RESULTS
  Several recent clinical trials have led to the approval of new inhaler therapies for COPD. Many of these are specifically targeting combination long-acting β-agonists and long-acting muscarinic antagonists for late stage COPD.
  
  
  CONCLUSIONS
  Several new bronchodilators are available on the market, especially in combination form. The new drug combinations have positive data though clinical relevance, and comparisons to available and well established therapies are still needed. Specifically, translating improved forced expiratory volume into meaningful clinical outcomes remains challenging.
authors.affiliation: Division of Pulmonary and Critical Care Medicine, University of Texas Southwestern, Dallas, Texas, USA.
authors.forename: Hetal J
authors.initials: HJ
authors.lastname: Patel
mesh_terms: D000818:Animals; D001993:Bronchodilator Agents / Q000493:pharmacokinetics / Q000627:therapeutic use; D005541:Forced Expiratory Volume; D006801:Humans; D018942:Macrolides / Q000493:pharmacokinetics / Q000627:therapeutic use; D018727:Muscarinic Antagonists / Q000493:pharmacokinetics / Q000627:therapeutic use; D009330:Nebulizers and Vaporizers; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*
chemical_list: D001993:Bronchodilator Agents; D018942:Macrolides; D018727:Muscarinic Antagonists